Abstracts Archive - Page 344 of 1683 - ATC Abstracts

2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
The Reperfusion Response in Plasma of Combined Heart/ Lung Transplanted Patients is Guided by Heart-Associated Cytokine Patterns on Contrast to the Ischemic Injury in Perfusion Solutions Following a Lung-Associated Pattern
C. Falk¹, J. Kühne², L. Radomsky², F. Wandrer², B. Wiegmann³, N. Ledwoch², J. Keil², K. Beushausen², F. Ius³, W. Sommer³, S. Rojas-Hernandez³, I. Tudorache³, A. Haverich³, G. Warnecke³
¹MHH, Institute of Transplant Immunology, Hannover, Germany, ²Institute of Transplant Immunology, Hannover Medical School MHH, Hannover, Germany, ³Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School MHH, Hannover, Germany
*Purpose: Organ-specific differences are discussed for ischemia/reperfusion injury (IRI) in cardiothoracic transplantation but rarely compared directly in a clinical setting. Therefore, we compared a cohort…
2020 American Transplant Congress
Post Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis
G. S. Liu¹, E. C. DePasquale¹, A. M. Wolfson², R. R. Chand³, P. Banankhah¹, J. Nattiv¹, A. D. Salimbangon⁴, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Cardiac sarcoidosis (CS) is a known etiology of end-stage dilated, hypertrophic, or arrhythmogenic cardiomyopathies requiring heart transplantation (HT). We sought to evaluate the long-term…
2020 American Transplant Congress
Risk Factors Associated with Hepatic Artery Thrombosis in the Modern Era
M. Krach, A. Kernodle, P. Chiang, D. Segev, A. Massie, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Historically, hepatic artery thrombosis (HAT) has been associated with certain risk factors, such as donor age, cold ischemia time, and split grafts; it is unclear…
2020 American Transplant Congress
Affect in Patients Awaiting Heart Transplant
A. Ahmed¹, D. S. Yip², B. W. Hardaway³, B. A. Boilson⁴, T. D. Schneekloth⁵, R. Benzo¹, R. Daly⁶, M. A. Hathcock⁷, B. K. Johnson⁷, K. Thompson⁸, C. C. Kennedy⁹
¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, ²Department of Transplantation, Mayo Clinic, Jacksonville, FL, ³Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ, ⁴Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁵Department of Psychiatry, Mayo Clinic, Rochester, MN, ⁶Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ⁷Department of Health Services Research -Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, ⁸Pulm onary Clinical Research Unit, Mayo Clinic, Rochester, MN, ⁹William J. von Liebig Center for Transplantation and Regenerative Medicine, Mayo Clinic, Rochester, MN
*Purpose: Affect refers to an individual’s emotional response .It may be categorized as positive or negative. Affect in heart transplant candidates is under-explored. We aimed…
2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
N. Murakami¹, G. Reid², A. Weins¹, B. Adam², M. Mengel², L. Riella¹
¹Brigham and Women's Hospital, Boston, MA, ²University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…
2020 American Transplant Congress
The Effect of UNOS Donor Policy Change on Distance from Recipient Hospital and the Effects on Mortality in Heart Transplantation
P. Kingsford¹, J. P. Li¹, C. J. Lum², A. D. Salimbangon³, G. S. Liu⁴, R. R. Chand⁵, P. Banankhah¹, P. A. Genyk¹, D. Vucicevic¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. Nattiv¹, S. Hashmi¹, S. B. Nuno¹, J. Pizula¹, D. J. Miklin¹, A. E. Lee¹, K. Yang¹, S. Shah¹, A. S. Vaidya¹, A. M. Wolfson⁶, E. C. DePasquale¹
¹LAC-USC, Los Angeles, CA, ²The Queens Medical Center, Honolulu, HI, ³UCLA Medical Center, Los Angeles, CA, ⁴USC, Los Angeles, CA, ⁵Harbor-UCLA Medical Center, Los Angeles, CA, ⁶University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: In light of the recent change in the UNOS allocation policy, we sought to evaluate the impact of distance from recipient hospital on mortality.*Methods:…
2020 American Transplant Congress
Alcohol Relapse after Liver Transplant for Alcohol-Related Cirrhosis: A Longitudinal Assessment of Risk Factors for Relapse and Long-Term Survival
B. Rice, N. Mehta, J. L. Dodge, J. D. Grab, C. Sherman
University of California San Francisco, San Francisco, CA
*Purpose: Relapse to alcohol after liver transplant (LT) is common but likely underreported in patients with alcohol-related cirrhosis (AC). The aim of this study was…
2020 American Transplant Congress
Evaluation of Optimization of Workflow for Timing of Inpatient Therapeutic Drug Monitoring of Maintenance Immunosuppressive Drugs in Abdominal Transplant Recipients
J. Schulte, S. Mehta, E. Vargas, K. Cunningham
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Therapeutic drug monitoring (TDM) is essential to the safety and efficacy of immunosuppressants (IS) given their narrow therapeutic index. After an internal review, it…
2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
A. K. Mezochow, P. L. Abt, T. Bittermann
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…